New-Onset Diabetes Mellitus With Exposure to Ledipasvir and Sofosbuvir.

Authors

Resmi Premji
Nira Roopnarinesingh
Nazia Qazi, George Washington University
Eric S. Nylen, George Washington UniversityFollow

Document Type

Journal Article

Publication Date

10-1-2015

Journal

Journal of Investigative Medicine High Impact Case Reports

Volume

3

Issue

4

DOI

10.1177/2324709615623300

Abstract

The combination therapy of ledipasvir/sofosbuvir was approved by the Food and Drug Administration in 2014 for the treatment of chronic hepatitis C. Although hyperglycemia is not well known to occur with its use, we present 2 cases of new-onset diabetes mellitus and a review of the literature suggesting an adverse event association. In the first patient with HIV, we postulate that ledipasvir/sofosbuvir increased the levels of tenofovir and thereby potentiated hyperglycemia. In the second case of a patient with prediabetes, ledipasvir/sofosbuvir appeared to increase insulin resistance. A literature review further supported an association of hyperglycemia and the use of ledipasvir/sofosbuvir. Hence, clinicians should be cautious about worsening of glucose intolerance, and more studies are warranted to explore the underlying mechanism.

Comments

Reproduced with permission of Sage . Journal of Investigative Medicine High Impact Case Reports

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.

APA Citation

Premji, R., Roopnarinesingh, N., Qazi, N., & Nylen, E. S. (2015). New-Onset Diabetes Mellitus With Exposure to Ledipasvir and Sofosbuvir.. Journal of Investigative Medicine High Impact Case Reports, 3 (4). http://dx.doi.org/10.1177/2324709615623300

Peer Reviewed

1

Open Access

1